Reduced decline of lung diffusing capacity in COPD patients with diabetes and metformin treatment.

Kahnert, Kathrin; Andreas, Stefan; Kellerer, Christina; Lutter, Johanna I; Lucke, Tanja; Yildirim, Önder; Lehmann, Mareike; Seissler, Jochen; Behr, Jürgen; Frankenberger, Marion; Bals, Robert; Watz, Henrik; Welte, Tobias; Trudzinski, Franziska C; Vogelmeier, Claus F; Alter, Peter; Jörres, Rudolf A

doi:10.1038/s41598-022-05276-x

User: Guest

Institut für Allgemeinmedizin (keine SAP-Zuordnung!)

Back
Back to start of result list
Permanent link for displayed object

Document type:: Article; Journal Article; Research Support, Non-U.S. Gov't
Author(s):: Kahnert, Kathrin; Andreas, Stefan; Kellerer, Christina; Lutter, Johanna I; Lucke, Tanja; Yildirim, Önder; Lehmann, Mareike; Seissler, Jochen; Behr, Jürgen; Frankenberger, Marion; Bals, Robert; Watz, Henrik; Welte, Tobias; Trudzinski, Franziska C; Vogelmeier, Claus F; Alter, Peter; Jörres, Rudolf A
Title:: Reduced decline of lung diffusing capacity in COPD patients with diabetes and metformin treatment.
Abstract:: We studied whether in patients with COPD the use of metformin for diabetes treatment was linked to a pattern of lung function decline consistent with the hypothesis of anti-aging effects of metformin. Patients of GOLD grades 1-4 of the COSYCONET cohort with follow-up data of up to 4.5 y were included. The annual decline in lung function (FEV1, FVC) and CO diffusing capacity (KCO, TLCO) in %predicted at baseline was evaluated for associations with age, sex, BMI, pack-years, smoking status, baseline lung function, exacerbation risk, respiratory symptoms, cardiac disease, as well as metformin-containing therapy compared to patients without diabetes and metformin. Among 2741 patients, 1541 (mean age 64.4 y, 601 female) fulfilled the inclusion criteria. In the group with metformin treatment vs. non-diabetes the mean annual decline in KCO and TLCO was significantly lower (0.2 vs 2.3, 0.8 vs. 2.8%predicted, respectively; p < 0.05 each), but not the decline of FEV1 and FVC. These results were confirmed using multiple regression and propensity score analyses. Our findings demonstrate an association between the annual decline of lung diffusing capacity and the intake of metformin in patients with COPD consistent with the hypothesis of anti-aging effects of metformin as reflected in a surrogate marker of emphysema.
Journal title abbreviation:: Sci Rep
Year:: 2022
Journal volume:: 12
Journal issue:: 1
Fulltext / DOI:: doi:10.1038/s41598-022-05276-x
Pubmed ID:: http://view.ncbi.nlm.nih.gov/pubmed/35082306
Print-ISSN:: 2045-2322
TUM Institution:: 587; 602; 604; Lehrstuhl für Allgemeinmedizin (Prof. Schneider) (keine SAP-Zuordnung!)
BibTeX